検索結果

nju is committed to obtaining marketing approval for the DED treatment SJP-0132 to provide patients with new options for alleviating the signs and symptoms of this disease. Mochida is dedicated to lev...

nju is committed to obtaining marketing approval for the DED treatment SJP-0132 to provide patients with new options for alleviating the signs and symptoms of this disease. Mochida is dedicated to lev...

Meetings of the Minds | Research & Development | SENJU Pharmaceutica

開催地：Salt Lake City, Utah, United States of America Establishment of in vitro drug evaluation model with retinal ganglion cells from Leber’s hereditary optic neuropathy (LHON) patient-derived iPSC R.I...

arpening algorithm. We aim to promote “more visibility” by providing products and services equipped with image sharpening and high-resolution algorithms in the future, emphasizing the importance of si...

arpening algorithm. We aim to promote “more visibility” by providing products and services equipped with image sharpening and high-resolution algorithms in the future, emphasizing the importance of si...